# Cabaletta Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Cabaletta Bio, Inc.). ## Overview Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases. Its core platform, CABA, is designed to selectively eliminate disease-causing B cells and plasma cells, with lead programs such as rese-cel being studied in indications including pemphigus vulgaris, myositis, systemic lupus erythematosus, generalized myasthenia gravis, systemic sclerosis, and related autoimmune disorders. The company has not yet generated product revenue and remains focused on advancing clinical trials, regulatory interactions, and manufacturing readiness. Cabaletta is also building a commercial-scale manufacturing strategy through CDMO partnerships and potential internal capabilities to support future supply if its programs are approved. ## Products & services • rese-cel (CABA-201) autologous CAR-T candidate • RESET clinical trial program for autoimmune diseases • CABA platform for engineered T-cell therapies • Clinical development services for autoimmune indications • Manufacturing process development and CDMO transfer - **Lead cell therapy candidate** (0%) — Autologous engineered T-cell therapy programs centered on rese-cel for autoimmune diseases. - **Clinical development programs** (0%) — RESET-branded clinical studies evaluating rese-cel across multiple autoimmune indications. - **Platform technology** (0%) — The CABA platform used to design and advance targeted cell therapies against pathogenic B cells and plasma cells. - **Manufacturing and process development** (0%) — Process transfer, scale-up, and supply-chain readiness work with CDMOs and potential internal facilities. - rese-cel (CABA-201) autologous CAR-T candidate - RESET clinical trial program for autoimmune diseases - CABA platform for engineered T-cell therapies - Clinical development services for autoimmune indications - Manufacturing process development and CDMO transfer ## Customers Cabaletta does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites, investigators, and patients enrolled in its studies. If approved, the eventual buyers would be specialty physicians, hospitals, and treatment centers managing severe autoimmune diseases that require advanced immunotherapy. Payers and health systems would also be important decision-makers because these therapies are likely to be high-cost, specialized treatments. The company’s business model depends on convincing clinicians that its targeted cell therapies can offer meaningful benefit versus existing immunosuppressive or biologic options. - **Clinical trial patients** (primary) — Patients with autoimmune diseases such as pemphigus vulgaris, myositis, SLE, MG, and systemic sclerosis who enroll in RESET studies to access investigational therapy. - **Clinical investigators and trial sites** (primary) — Academic and specialty centers that recruit, treat, and monitor patients in Cabaletta’s clinical programs. - **Specialty autoimmune physicians** (secondary) — Rheumatologists, neurologists, dermatologists, and related specialists who would prescribe or refer patients if products are approved. - **Hospitals and treatment centers** (secondary) — Centers capable of handling cell therapy administration, monitoring, and patient support for complex autoimmune indications. - **Payers and reimbursement decision-makers** (secondary) — Insurers and health systems that would determine access and coverage for a high-cost advanced therapy. - Clinical trial investigators and sites running RESET studies - Patients with severe autoimmune diseases enrolled in trials - Specialty physicians treating refractory autoimmune conditions - Hospitals and treatment centers that would administer future therapy - Payers and health systems that would evaluate reimbursement - Potential licensing or collaboration partners for the platform ## Geography Cabaletta is headquartered in the United States and its reported operating footprint is centered on U.S.-based clinical development, manufacturing coordination, and corporate functions. The company also references international operations in its staffing and cost discussion, indicating some non-U.S. activity tied to development and manufacturing support. Manufacturing readiness depends on third-party partners such as Lonza and Minaris, so geography matters mainly through where clinical sites, CDMOs, and regulatory interactions are located. Because the company is pre-revenue, there is no disclosed country revenue mix to map. - Headquartered in the United States - Clinical development and corporate operations are primarily U.S.-based - International operations are mentioned in headcount and cost growth - Manufacturing depends on third-party partners such as Lonza and Minaris - No product revenue has been generated, so no country revenue mix is disclosed ## Strategy Cabaletta’s strategy is to advance rese-cel through multiple RESET clinical trials and build enough clinical evidence to support regulatory approval in autoimmune diseases. A major priority is manufacturing readiness, including transfer of an improved process to Lonza and evaluation of multiple scale-up options such as additional CDMOs, leased facilities, or an owned manufacturing site. The company is also broadening the pipeline across several autoimmune indications, which can increase the value of the platform if one program validates the approach. Because it has no product revenue, capital preservation and access to financing remain central to executing the development plan. - **Advance lead clinical programs** (short-term) — Clinical proof-of-concept is the main value driver for a pre-revenue biotech and is required for any regulatory path. - **Build scalable manufacturing capability** (short-term) — Cell therapy commercialization depends on reliable, compliant, and scalable supply. - **Broaden platform applicability** (medium-term) — Multiple autoimmune indications can diversify clinical risk and increase the long-term commercial opportunity. - **Maintain financing flexibility** (short-term) — The company expects continued cash burn before any product revenue and needs capital to fund trials and manufacturing. - Advance rese-cel through RESET clinical trials across autoimmune indications - Generate clinical data that can support regulatory filings and future commercialization - Transfer and scale manufacturing to support clinical and eventual commercial supply - Use multiple manufacturing options to reduce dependence on a single partner - Expand the CABA platform across additional autoimmune diseases - Preserve cash and secure financing to fund development through key milestones ## Risks Cabaletta faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the possibility that its programs never reach commercialization. Its dependence on third-party manufacturers creates supply, quality, and facility-approval risk, and any disruption could delay trials or future launch plans. Even if approved, the company may face physician reluctance, payer pressure, and competition from other therapies in development for the same autoimmune diseases. Because it has no product revenue and limited operating history, financing risk and dilution remain material until the business can generate durable clinical or commercial value. - **Early-stage clinical development risk** [critical] — The company is still testing whether rese-cel can show safety and efficacy across autoimmune indications. - **Manufacturing and supply chain dependence** [high] — Cabaletta relies on CDMOs and third parties for production, release testing, and process transfer. - **Competition in autoimmune therapeutics** [high] — Other biopharmaceutical companies are developing therapies for PV, MG, SLE, myositis, SSc, gMG, and MS. - **Financing and dilution risk** [high] — The company has no product revenue and will need additional capital to fund trials and manufacturing scale-up. - Clinical trial failure or delay could prevent approval and destroy program value - Regulatory risk is high because cell therapies require extensive FDA review - Third-party manufacturing dependence can disrupt supply, quality, or timelines - Competing autoimmune therapies may limit adoption and pricing power - Physician and patient acceptance may be slow for a novel treatment approach - Ongoing financing needs could dilute shareholders or constrain execution ## Accounting Cabaletta is a pre-revenue development-stage company, so the most important accounting issue is the timing and classification of research and development spending rather than revenue recognition. It expenses R&D as incurred, but certain outsourced clinical and manufacturing costs are recognized based on vendor progress, which can create quarter-to-quarter volatility. Stock-based compensation, severance, and lease-related finance costs also affect operating expense trends and can obscure underlying cash burn. Because the company has significant cash, cash equivalents, and investments, interest income and fair-value-related investment accounting can also move reported results, while lease accounting for manufacturing arrangements affects both liabilities and interest expense. - **Research and development expense recognition** — Can cause significant quarterly fluctuation in operating expenses and cash burn - **Stock-based compensation** — Affects reported operating loss and comparability across periods - **Lease accounting for manufacturing arrangements** — Impacts leverage presentation and operating cost structure - **Interest income on cash and investments** — Can partially offset operating losses and vary with cash deployment timing - No product revenue has been generated, so revenue recognition is not yet a driver - R&D is expensed as incurred, creating high operating expense volatility - Outsourced clinical and manufacturing work may be accrued based on progress estimates - Stock-based compensation is a meaningful non-cash expense for a biotech of this stage - Finance lease accounting for manufacturing arrangements affects interest expense and liabilities - Investment balances and interest income can materially affect non-operating results --- *Last updated: 2026-04-28T14:25:05.192279+00:00*